Obat obesitas 'kuda troya' tingkatkan penurunan berat badan pada tikus

Jumat, 08 Mei 2026

Dilaporkan oleh AI

Para ilmuwan telah mengembangkan pengobatan obesitas hibrida yang menggunakan sinyal GLP-1 dan GIP untuk mengirimkan peningkat metabolisme langsung ke dalam sel. Uji coba awal pada tikus menunjukkan penurunan berat badan yang lebih besar dan kontrol gula darah yang lebih baik dibandingkan terapi standar. Pendekatan ini bertujuan untuk mengurangi efek samping dengan membatasi kerja obat pada area yang ditargetkan.

Para peneliti di Helmholtz Munich menciptakan senyawa tersebut dengan menghubungkan molekul berbasis inkretin dengan lanifibranor, yaitu agonis pan-PPAR. Desain ini berfungsi seperti kuda troya, yang memungkinkan obat tambahan tersebut memasuki sel melalui reseptor GLP-1 atau GIP sebelum mengaktifkan sakelar yang mengatur metabolisme lemak dan gula di dalam nukleus.

Updated POWER framework urges multidisciplinary obesity care beyond GLP-1 drugs

Sabtu, 20 Juni 2026 Dilaporkan oleh AI Gambar dihasilkan oleh AI Fakta terverifikasi

A new Gastroenterology commentary revisits the American Gastroenterological Association’s 2017 POWER framework, arguing that GLP-1 medicines should be integrated with endoscopic therapies, bariatric surgery and precision medicine to improve long-term obesity outcomes.

Oral GLP-1 pill shows strong results in diabetes trial

A new experimental oral medication called elecoglipron improved blood sugar control and promoted weight loss in adults with type 2 diabetes during a phase 2b trial. Results from the SOLSTICE study were presented at the American Diabetes Association's Scientific Sessions and published in The Lancet.

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

Jumat, 08 Mei 2026 Dilaporkan oleh AI Fakta terverifikasi

A year-long observational study in Japan suggests that people with type 2 diabetes who tend to overeat in response to tempting food cues such as sight and smell may see greater weight loss—and possibly better blood-sugar improvement—after starting GLP-1 receptor agonists, while those with primarily emotional eating patterns show less consistent links to long-term outcomes.

Health

Study links Ozempic to lower depression and anxiety risks

Asia

Young Indians risk health with Ozempic, Mounjaro for pre-wedding weight loss

Health

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Study finds GLP-1 hormone at very low levels in arthritic joint fluid

Researchers at Aarhus University report that the hormone GLP-1—mimicked by drugs such as Wegovy—can be measured in the joint fluid of patients with inflammatory arthritis, but only at very low levels. The findings, published in The Lancet Rheumatology, suggest GLP-1–based medicines might eventually be studied for potential direct effects on joint inflammation, though the researchers say clinical trials are needed to show whether such treatment works.

Study links PAM gene variants to weaker blood-sugar response to GLP-1 drugs such as Ozempic

Jumat, 05 Juni 2026 Dilaporkan oleh AI Fakta terverifikasi

Researchers say genetic variants in the PAM gene may help explain why some people with Type 2 diabetes get less blood-sugar benefit from GLP-1 receptor agonist drugs such as Ozempic, a phenomenon they describe as “GLP-1 resistance.”

14 Juni 2026 20.53